References
- [1] Behnke CA, Le Trong I, Godden JW, et al. Atomic resolution studies of carbonic anhydrase II. Acta Crystallogr. 2010;66:616-627.
- [2] Ceruso M, Vullo D, Scozzafava A, Supuran CT. Inhibition of human carbonic anhydrase isoforms I-XIV with sulfonamides incorporating fluorine and 1,3,5-triazine moieties. Bioorg Med Chem. 2013;21:6929-6936.
- [3] Covarrubias AS, Bergfors T, Jones TA, Hogbom M. Structural mechanics of the pH-dependent activity of beta-carbonic anhydrase from Mycobacterium tuberculosis. J Biol Chem. 2006;281:4993-4999.
- [4] Covarubias AS, Larsson AM, Hogbom M, et al. Structure and Function of Carbonic Anhydrases from Mycobacterium tuberculosis. J Biol Chem. 2005;280:18782-18789.
- [5] Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes. J Med Chem. 2006;49:6177-6196.
- [6] Keckesova S, Sedlarova E, Cizmarik J, et al. Antimycobacterial activity of novel derivatives of arylcarbonyloxyaminopro-panols. Ceska Slov Farm. 2009;58:203-207.
- [7] Li J, Abel R, Zhu K, et al. The VSGB 2.0 Model: A Next Generation Energy Model for High Resolution Protein Structure Modelling. Proteins 2011;79:2794-2812.
- [8] Lipinski C, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3-26.
- [9] Maresca A. Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with. Bioorg Med Chem Lett. 2009;19:4929-4932.
- [10] Sassetti CM, Rubin EJ. Genetic requirements for mycobacterial survival during infection. Proc Natl Acad Sci U S A. 2003;100:12989-12994.
- [11] Shelley JC, Cholleti A, Frye L, Greenwood JR, Timlin MR, Uchimaya M. Epik: a software program for pKa prediction and protonation state generation for drug-like molecules. J Comp-Aided Mo. Design. 2007;21:681-691.
- [12] Showalter HD, Denny WA. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis (Edinb). 2008;88(1 suppl):s3- s17.
- [13] Supuran CT. Carbonic anhydrases - An overview. Curr Pharm Des. 2008;14:603-614.
- [14] Supuran CT. Carbonic Anhydrase Inhibition/Activation: Trip of a Scientist Around the World in the Search of Novel Chemotypes and Drug Targets. Curr Pharm Des. 2010;16:3233-3245.
- [15] Upadhayaya RS, Kulkarni GM, Vasireddy NR, Vandavasi JK, Dixit SS, Sharma V, Chattopadhyaya J. Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis. Bioorg Med Chem 2009;17:4681-4692.
- [16] Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45:2615-2623.
- [17] Waisser K, Dolezal R, Palat K, Cizmarik J, Kaustova J. QSAR study of antimycobacterial activity of quaternary ammonium salts of piperidinylethyl esters of alkoxysubstituted phenylcarbamic acids. Folia Microbiologica. 2006;51:21-24.
- [18] WHO. WHO Global tuberculosis report. WHO; 2013.